Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2016

04.06.2016 | Original Article

Surgical outcome of patients with lung cancer involving the left atrium

verfasst von: Takuma Tsukioka, Makoto Takahama, Ryu Nakajima, Michitaka Kimura, Hidetoshi Inoue, Ryoji Yamamoto

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Pulmonary and left atrial resection is not yet an established treatment for patients with primary lung cancer involving the left atrium. We investigated the clinical course of patients with primary lung cancer involving the left atrium who were treated with pulmonary resection and partial atrial resection.

Methods

From January 1996 to December 2013, 51 patients underwent extended resection for lung cancer that invaded the surrounding organs. Of these, we focused on 12 patients who underwent surgical treatment for lung cancer involving the left atrium. The clinical course of each of these patients was investigated retrospectively.

Results

The most common histological subtype was squamous cell carcinoma. Pneumonectomy was performed in nine patients, and right middle and lower lobectomy was performed in three patients. Complete resection was performed in 11 patients (92 %). Postoperative complications were observed in four patients (33 %)—prolonged air leakage in two patients, broncho-pleural fistula in one patient, and empyema in one patient. There were no surgical deaths. This study involved seven patients with pathological N0–1 disease and five patients with pathological N2 disease. The postoperative 5-year survival rate was 46 % in all patients. The 5-year survival rates in patients with pathological N0–1 disease and N2 disease were 67 and 20 %, respectively.

Conclusion

Because treatment-related death was not observed and outcome was fair in patients with N0–1 disease, surgical resection for primary lung cancer involving the left atrium may be acceptable in selected patients. Further investigations are required to improve the outcome of surgical treatment for patients with primary lung cancer involving the left atrium.
Literatur
1.
Zurück zum Zitat Tsuchiya R, Asamura H, Kondo H et al (1994) Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 57:960–965CrossRefPubMed Tsuchiya R, Asamura H, Kondo H et al (1994) Extended resection of the left atrium, great vessels, or both for lung cancer. Ann Thorac Surg 57:960–965CrossRefPubMed
2.
Zurück zum Zitat Bobbio A, Carbognani P, Grapeggia M et al (2004) Surgical outcome of combined pulmonary and atrial resection for lung cancer. Thorac Cardiovasc Surg 52:180–182CrossRefPubMed Bobbio A, Carbognani P, Grapeggia M et al (2004) Surgical outcome of combined pulmonary and atrial resection for lung cancer. Thorac Cardiovasc Surg 52:180–182CrossRefPubMed
3.
Zurück zum Zitat Ratto GB, Costa R, Vassallo G et al (2004) Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer. Ann Thorac Surg 78:234–237CrossRefPubMed Ratto GB, Costa R, Vassallo G et al (2004) Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer. Ann Thorac Surg 78:234–237CrossRefPubMed
4.
Zurück zum Zitat Spaggiari L, D’ Aiuto M, Veronesi G et al (2005) Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg 79:234–240CrossRefPubMed Spaggiari L, D’ Aiuto M, Veronesi G et al (2005) Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. Ann Thorac Surg 79:234–240CrossRefPubMed
5.
Zurück zum Zitat Wu L, Xu Z, Zhao X et al (2009) Surgical treatment of lung cancer invading the left atrium or base of the pulmonary vein. World J Surg 33:492–496CrossRefPubMed Wu L, Xu Z, Zhao X et al (2009) Surgical treatment of lung cancer invading the left atrium or base of the pulmonary vein. World J Surg 33:492–496CrossRefPubMed
6.
Zurück zum Zitat Kuehnl A, Lindner M, Hornung HM et al (2010) Atrial resection for lung cancer: morbidity, mortality, and long-term follow-up. World J Surg 34:2233–2239CrossRefPubMed Kuehnl A, Lindner M, Hornung HM et al (2010) Atrial resection for lung cancer: morbidity, mortality, and long-term follow-up. World J Surg 34:2233–2239CrossRefPubMed
7.
Zurück zum Zitat Stella F, Dell’Amore A, Caroli G et al (2012) Surgical results and long-term follow-up of T(4)-non-small cell lung cancer invading the left atrium or the intrapericardial base of the pulmonary veins. Interact CardioVasc Thorac Surg 14:415–419CrossRefPubMedPubMedCentral Stella F, Dell’Amore A, Caroli G et al (2012) Surgical results and long-term follow-up of T(4)-non-small cell lung cancer invading the left atrium or the intrapericardial base of the pulmonary veins. Interact CardioVasc Thorac Surg 14:415–419CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Galvaing G, Tardy MM, Cassagnes L et al (2014) Left atrial resection for T4 lung cancer without cardiopulmonary bypass: technical aspects and outcomes. Ann Thorac Surg 97:1708–1713CrossRefPubMed Galvaing G, Tardy MM, Cassagnes L et al (2014) Left atrial resection for T4 lung cancer without cardiopulmonary bypass: technical aspects and outcomes. Ann Thorac Surg 97:1708–1713CrossRefPubMed
9.
Zurück zum Zitat Söndergaard T, Wälti R (1967) Circumclusion of atrial septal defects. Thoraxchir Vask Chir 15:569–575 (Article in German) PubMed Söndergaard T, Wälti R (1967) Circumclusion of atrial septal defects. Thoraxchir Vask Chir 15:569–575 (Article in German) PubMed
10.
Zurück zum Zitat Kauffmann M, Krüger T, Aebert H (2013) Surgery on extracorporeal circulation in early and advanced non-small cell lung cancer. Thorac Cardiovasc Surg 61:103–108CrossRefPubMed Kauffmann M, Krüger T, Aebert H (2013) Surgery on extracorporeal circulation in early and advanced non-small cell lung cancer. Thorac Cardiovasc Surg 61:103–108CrossRefPubMed
11.
Zurück zum Zitat Muralidaran A, Detterbeck FC, Boffa DJ et al (2011) Long-term survival after lung resection for non-small cell lung cancer with circulatory bypass: a systematic review. J Thorac Cardiovasc Surg 142:1137–1142CrossRefPubMed Muralidaran A, Detterbeck FC, Boffa DJ et al (2011) Long-term survival after lung resection for non-small cell lung cancer with circulatory bypass: a systematic review. J Thorac Cardiovasc Surg 142:1137–1142CrossRefPubMed
12.
Zurück zum Zitat Akchurin RS, Davidov MI, Partigulov SA et al (1997) Cardiopulmonary bypass and cell-saver technique in combined oncologic and cardiovascular surgery. Artif Organs 21:763–765CrossRefPubMed Akchurin RS, Davidov MI, Partigulov SA et al (1997) Cardiopulmonary bypass and cell-saver technique in combined oncologic and cardiovascular surgery. Artif Organs 21:763–765CrossRefPubMed
Metadaten
Titel
Surgical outcome of patients with lung cancer involving the left atrium
verfasst von
Takuma Tsukioka
Makoto Takahama
Ryu Nakajima
Michitaka Kimura
Hidetoshi Inoue
Ryoji Yamamoto
Publikationsdatum
04.06.2016
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0992-y

Weitere Artikel der Ausgabe 6/2016

International Journal of Clinical Oncology 6/2016 Zur Ausgabe

Letter to the Editor

Prevalence of data fraud

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.